Psychedelics

Psychedelics

Psychedelics: A Breakthrough in Anti-Inflammatory Treatment, A New Era of Therapy

Psychedelics (psilocybin, MDMA, LSD, ketamine) are returning after 60 years of prohibition as breakthrough drugs in treatment-resistant depression, PTSD, and potentially inflammatory diseases. Mechanism 5-HT2A, neuroplasticity, COMPASS Pathways and MAPS studies, legal status in Poland and the EU in 2026.

Michał Waluk
2026-05-11

Psychedelic Therapy 2026: MDMA, Psilocybin, Phase III Studies, FDA and Status in Poland - Psychedelics

Psychedelics, Medical and health applications

Psychedelic Therapy 2026: MDMA, Psilocybin, Phase III Trials, FDA and Status in Poland

Psychedelic Therapy 2026: MDMA in PTSD (MAPS Mitchell 2023), psilocybin in treatment-resistant depression (NEJM Goodwin 2022). Phase III results, FDA decision, risks, legality in Poland.

Michał Waluk
2026-05-06

Psychedelics, Medical and health applications

Psilocybin in Psychotherapy 2026: Johns Hopkins Research, NEJM, Effectiveness and Legality in Poland

Psilocybin in psychotherapy 2026: RCT Carhart-Harris 2021, NEJM 2022, COMP360 Goodwin. 71% clinical response in treatment-resistant depression. Legal status in Poland and risks.